COVID Long Haul Management with PD-1 Blockers | Ex-Vivo Study

COVID Long Haul Management with PD-1 Blockers | Ex-Vivo Study

In this important work the researchers explored the immune dysregulation observed in the COVID long-haul patients. They then used PD-1 blockers to explore if the dysregulated immune system could be restored. Let's review their study.

If you like this content and want more, I am doing a special lifetime membership offer. Click here:
https://www.drbeen.com/yt-special/

Link to the FDA channel: https://www.youtube.com/watch?v=DfdMsAqkneE

Want to support this work?:
Buy me a coffee :-) https://www.buymeacoffee.com/DrMobeenSyed
Become my patron: https://www.patreon.com/mobeensyed?fan_landing=true
PayPal: https://paypal.me/mobeensyed?locale.x=en_US

My substack: https://mobeensyedmd.substack.com/

#drbeen #koolbeens #COVID

Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.


URL list from Thursday, Jun. 9 2022

DrBeen: Medical Education Online
https://www.drbeen.com/

PD-1 blockade counteracts post–COVID-19 immune abnormalities and stimulates the anti–SARS-CoV-2 immune response - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783674/

microRNA - Wikipedia
https://en.wikipedia.org/wiki/MicroRNA

Immune Checkpoint Inhibitors and Their Side Effects
https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html